A decision to sell more shares to the public this week didn't help bluebird bio's (NASDAQ: BLUE) sagging share price this year. The equity offering dilutes investors and throws cold water on hopes that an acquisition will happen soon. Nevertheless, bluebird bio remains on track to file for FDA approval of two gene therapy drugs in the next year, and trials for these drugs so far suggest they could be big successes.
Comment on Did This Top Biotech Stock Just Go on Sale?
newsfeedback@fool.com (Todd Campbell), The Motley Fool
Wed, 07/25/2018 - 4:00am
Welcome to Wopular
Wopular is an
online newspaper rack,
giving you a summary view of the top headlines from the top news sites.
Senh Duong (Founder)
Wopular,
MWB,
RottenTomatoes
MoviesWithButter : Our Sister Site
- "Expendables 4" Starts Shooting This Fall, Says Randy Couture at the Arnold Sports Festival more
- “Expendables 4” Gets Funding Interest from “Ip Man 3” Financier more
- "Ip Man 3" Distributor Suspected of Box Office Fraud, Parent Company Loses $200M in Market Cap more
- Yen Targets "Ip Man 4" for 2018 Release; Discusses Film with Director, Producer more
- "Ip Man 3" Shatters Expectations with $72M Opening [China Box Office] more